Quetiapine fumarate (Seroquel) SR

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Affective Psychosis, Bipolar

Conditions

Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis, Psychoses, Manic-Depressive

Trial Timeline

Dec 1, 2006 → Jun 1, 2007

About Quetiapine fumarate (Seroquel) SR

Quetiapine fumarate (Seroquel) SR is a phase 3 stage product being developed by AstraZeneca for Affective Psychosis, Bipolar. The current trial status is completed. This product is registered under clinical trial identifier NCT00422214. Target conditions include Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis.

What happened to similar drugs?

2 of 7 similar drugs in Affective Psychosis, Bipolar were approved

Approved (2) Terminated (0) Active (5)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00422123Phase 3Completed
NCT00422214Phase 3Completed

Competing Products

14 competing products in Affective Psychosis, Bipolar

See all competitors